RT Journal Article
SR Electronic
T1 Longitudinal Changes in Health-related Quality of Life After <sup>125</sup>I Low-dose-rate Brachytherapy for Localized Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6443
OP 6456
DO 10.21873/anticanres.14666
VO 40
IS 11
A1 NAOYUKI OGASAWARA
A1 MAKOTO NAKIRI
A1 HIROFUMI KUROSE
A1 KOSUKE UEDA
A1 KATSUAKI CHIKUI
A1 KIYOAKI NISHIHARA
A1 MITSUNORI MATSUO
A1 SHIGETAKA SUEKANE
A1 KENTA MUROTANI
A1 KOICHIRO MURAKI
A1 CHIKAYUKI HATTORI
A1 ETSUYO OGO
A1 TUKASA IGAWA
A1 TATSUYA ISHITAKE
YR 2020
UL http://ar.iiarjournals.org/content/40/11/6443.abstract
AB Background/Aim: The factors associated with longitudinal changes in health-related quality of life (HRQOL) are unclear. In this study we aimed to evaluate the longitudinal changes and predictors of HRQOL after 125I low-dose-rate brachytherapy (LDB) for localised prostate cancer (PCA). Patients and Methods: We evaluated 180 patients with localised PCA treated with LDB. The HRQOL was evaluated at 3 weeks before LDB and at 1, 3, 6, 12, 18, 24, 36, and 48 months after LDB using the International Prostate Symptom Score, Medical Outcome Study 8-Items Short Form Health Survey (SF-8), and University of California Los Angeles Prostate Cancer Index (UCLA-PCI). Results: All HRQOL scores, except for UCLA-PCI sexual function and SF-8 mental component summary (MCS), were improved to baseline after an early transient deterioration. In contrast, the sexual function did not return to baseline after early deterioration. Meanwhile, the MCS scores showed no significant decline after implantation and trended upward. The prostate V100 and baseline UCLA-PCI sexual function scores predicted a clinically significant decrease in sexual function in the late post-implantation period. Conclusion: Most aspects of the HRQOL of PCA patients who underwent LDB improved to baseline. The results that V100 and baseline sexual function were predictors of late post-LDB may provide more accurate information for patients with preserved sexual function before treatment and for their partners.